Comparative Pharmacology
Head-to-head clinical analysis: OXY KESSO TETRA versus VIBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXY KESSO TETRA versus VIBRAMYCIN.
OXY-KESSO-TETRA vs VIBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, though it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Oxycodone is combined with aspirin (OXY-KESSO-TETRA) for analgesic synergy.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing addition of amino acids to the growing peptide chain. Bacteriostatic.
200 mg orally every 8 hours for 10 days.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily; severe infections: 100 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life approximately 8-12 hours in adults with normal renal function; prolonged to 20-40 hours in moderate to severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Terminal elimination half-life is 16-18 hours in patients with normal renal function. Prolonged to 20-36 hours in severe renal impairment; no significant change in hepatic impairment.
Primarily renal (60-70% as unchanged drug) via glomerular filtration and tubular secretion; approximately 20-30% is metabolized hepatically with metabolites excreted renally; less than 5% eliminated via bile/feces.
Approximately 40% excreted unchanged in urine via glomerular filtration; 20-25% eliminated in feces via biliary secretion; remainder metabolized. Renal clearance is about 30 mL/min.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic